^
    Back
    Association details:
    Biomarker:TNFRSF17 expression
    Cancer:Multiple Myeloma
    Drug:pamlectabart tismanitin (HDP-101) (RNA polymerase 2 inhibitor, BCMA-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Blood
    Title:

    Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

    Published date:
    11/15/2022
    Excerpt:
    In vitro cytotoxic potency of HDP-101 was demonstrated on BCMA-positive myeloma cell lines, as well as on non-proliferating primary CD138+ cells isolated from patients with refractory myeloma.
    DOI:
    https://doi.org/10.1182/blood-2022-168848
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Blood
    Title:

    Preclinical Evaluation of Hdp-101, a Novel Anti-BCMA Antibody-Drug Conjugate, in Multiple Myeloma

    Excerpt:
    In vitro cytotoxic potency of HDP-101 was tested on several BCMA-positive myeloma cell lines...Profound cytotoxic effects were seen at pico- to nanomolar concentrations of HDP-101 even in myeloma cells with low epitope density.
    DOI:
    https://doi.org/10.1182/blood.V130.Suppl_1.3070.3070